Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs JPMorgan Chase & Co (JPM) Price & Performance

Incyte CorporationTrade
JPMorgan Chase & CoTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs JPMorgan Chase & Co — how do they compare? Incyte Corporation trades at $120.59 (market cap $24.54B), while JPMorgan Chase & Co trades at $364.85 (market cap $962.37B). The key difference: JPMorgan Chase & Co is far larger — about 39.2× Incyte Corporation's market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

INCYJPM
Market Cap
$24.54B$962.37B
Sector
HealthFinancials
52-Week High
$129.93$362.04
52-Week Low
$81.61$282.84
Enterprise Value
$20.04B
Volume
10,479,943
Dividend Yield
1.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.

Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.

JPMorgan Chase & Co

JPMorgan Chase & Co. (JPM) trades at $365.11, up 1.48% in 24 hours, with a bullish technical signal and strong fundamentals including a 33.38% net income margin and 18.43% ROE. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Moderate Buy with a $374.18 price target. CEO Jamie Dimon's shareholder letter highlights economic risks, but institutional buying and resilient sector performance support optimism.

The outlook for JPM is positive, driven by earnings momentum and sector strength, though risks include geopolitical tensions and potential economic headwinds noted by management. Upside to the consensus target offers opportunity, but investors should weigh high RSI levels and macroeconomic cautions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About JPMorgan Chase & Co

JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.

Read more on JPM